Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production
Kraig Biocraft Laboratories (OTCQB: KBLB) is finalizing a significant three-year collaboration agreement with a Southeast Asian government agency to expand its recombinant spider silk production. The agreement, expected to be signed by end of July 2025, will provide access to new rearing facilities, infrastructure, and technical resources.
The partnership aims to optimize and scale spider silk production through parallel rearing operations, eliminating single points of failure in the supply chain. The collaboration includes creating multiple independent facilities for parent strain and egg production, enhancing supply chain security and increasing throughput capacity. Work under this agreement is scheduled to begin in August 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) sta finalizzando un importante accordo di collaborazione triennale con un'agenzia governativa del Sud-est asiatico per ampliare la produzione di seta di ragno ricombinante. L'accordo, che si prevede sar脿 firmato entro la fine di luglio 2025, garantir脿 l'accesso a nuove strutture di allevamento, infrastrutture e risorse tecniche.
La partnership punta a ottimizzare e aumentare la produzione di seta di ragno attraverso operazioni di allevamento parallele, eliminando i punti critici unici nella catena di approvvigionamento. La collaborazione prevede la creazione di pi霉 strutture indipendenti per la produzione delle linee parentali e delle uova, migliorando la sicurezza della catena di approvvigionamento e aumentando la capacit脿 produttiva. I lavori previsti da questo accordo inizieranno nell'agosto 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) est谩 finalizando un importante acuerdo de colaboraci贸n de tres a帽os con una agencia gubernamental del sudeste asi谩tico para expandir su producci贸n de seda de ara帽a recombinante. Se espera que el acuerdo se firme antes de finales de julio de 2025 y proporcionar谩 acceso a nuevas instalaciones de cr铆a, infraestructura y recursos t茅cnicos.
La asociaci贸n tiene como objetivo optimizar y escalar la producci贸n de seda de ara帽a mediante operaciones de cr铆a paralelas, eliminando puntos 煤nicos de fallo en la cadena de suministro. La colaboraci贸n incluye la creaci贸n de m煤ltiples instalaciones independientes para la producci贸n de cepas parentales y huevos, mejorando la seguridad de la cadena de suministro y aumentando la capacidad de producci贸n. El trabajo bajo este acuerdo est谩 programado para comenzar en agosto de 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB)電� 霃欕偍鞎勳嫓鞎� 鞝曤秬 旮瓣磤瓿� 3雲勱皠鞚� 欷戩殧頃� 順戨牓 瓿勳暯鞚� 毵堧毽晿瓿� 鞛堨溂氅�, 鞛“頃� 瓯半欷� 靸濎偘鞚� 頇曤寑頃� 鞓堨爼鞛呺媹雼�. 鞚� 瓿勳暯鞚� 2025雲� 7鞗� 毵愱箤歆� 觳搓舶霅� 鞓堨爼鞚措┌, 靸堧鞖� 靷湣 鞁滌劋, 鞚疙攧霛� 氚� 旮办垹 鞛愳洂鞐� 雽�頃� 鞝戧芳 甓岉暅鞚� 鞝滉车頃╇媹雼�.
鞚� 韺岉姼雱堨嫮鞚� 氤戨牞 靷湣 鞛戩梾鞚� 韱淀暣 瓯半欷� 靸濎偘鞚� 斓滌爜頇旐晿瓿� 頇曥灔頃橂姅 瓴冹潉 氇╉憸搿� 頃橂┌, 瓿店笁毵� 雮� 雼澕 鞁ろ尐 歆�鞝愳潉 鞝滉卑頃╇媹雼�. 順戨牓鞐愲姅 攵�氇� 攴犾＜ 氚� 鞎� 靸濎偘鞚� 鞙勴暅 鞐煬 霃呺 鞁滌劋鞚� 毵岆摐電� 瓴冹澊 韽暔霅橃柎 瓿店笁毵� 氤挫晥鞚� 臧曧檾頃橁碃 觳橂Μ 鞖╇焿鞚� 歃濌皜鞁滍偟雼堧嫟. 鞚� 瓿勳暯鞐� 霐半ジ 鞛戩梾鞚� 2025雲� 8鞗旍棎 鞁滌瀾霅� 鞓堨爼鞛呺媹雼�.
Kraig Biocraft Laboratories (OTCQB : KBLB) est en train de finaliser un accord de collaboration majeur de trois ans avec une agence gouvernementale d'Asie du Sud-Est pour 茅tendre sa production de soie d'araign茅e recombinante. L'accord, qui devrait 锚tre sign茅 d'ici fin juillet 2025, offrira un acc猫s 脿 de nouvelles installations d'茅levage, infrastructures et ressources techniques.
Le partenariat vise 脿 optimiser et augmenter la production de soie d'araign茅e gr芒ce 脿 des op茅rations d'茅levage parall猫les, 茅liminant ainsi les points uniques de d茅faillance dans la cha卯ne d'approvisionnement. La collaboration comprend la cr茅ation de plusieurs installations ind茅pendantes pour la production des souches parentales et des 艙ufs, renfor莽ant la s茅curit茅 de la cha卯ne d'approvisionnement et augmentant la capacit茅 de production. Les travaux dans le cadre de cet accord devraient d茅buter en ao没t 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) steht kurz vor dem Abschluss einer bedeutenden dreij盲hrigen Kooperationsvereinbarung mit einer Regierungsbeh枚rde in S眉dostasien zur Erweiterung der Produktion von rekombinantem Spinnenseide. Die Vereinbarung, die voraussichtlich bis Ende Juli 2025 unterzeichnet wird, erm枚glicht den Zugang zu neuen Aufzuchtanlagen, Infrastruktur und technischen Ressourcen.
Die Partnerschaft zielt darauf ab, die Produktion von Spinnenseide zu optimieren und zu skalieren durch parallele Aufzuchtoperationen, um einzelne Ausfallstellen in der Lieferkette zu vermeiden. Die Zusammenarbeit umfasst die Einrichtung mehrerer unabh盲ngiger Einrichtungen f眉r die Produktion von Elterntieren und Eiern, was die Sicherheit der Lieferkette verbessert und die Durchsatzkapazit盲t erh枚ht. Die Arbeiten im Rahmen dieser Vereinbarung sollen im August 2025 beginnen.
- Strategic access to new government rearing facilities and technical resources
- Implementation of parallel rearing operations to eliminate single points of failure
- Enhanced supply chain security through multiple independent facilities
- Increased production capacity and throughput potential
- Agreement not yet finalized, pending final signature
- Dependent on foreign government collaboration for expansion
- Implementation timeline and specific production targets not disclosed
ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement with a key government agency in Southeast Asia to expand the scale and security of its recombinant spider silk manufacturing platform.
This landmark agreement, expected to be signed before the end of July, marks the culmination of years of relationship-building and demonstrated performance by Kraig Labs and its proprietary spider silk technologies. The agreement is designed to accelerate the Company's growth by providing access to previously unavailable rearing facilities, supporting infrastructure, and technical resources.
Under the terms of this collaboration, Kraig Labs will work closely with government specialists to optimize and expand spider silk production. The collaboration will unlock new production capacity, enabling Kraig Labs to significantly scale its hybridized silkworm operations.
Importantly, this agreement also includes provisions for the creation of parallel rearing operations, a key component in the Company鈥檚 long-term roadmap to mitigate production risk and eliminate single points of failure. By distributing parent strain and egg production across multiple independent facilities, Kraig Labs is further securing its supply chain and increasing throughput capacity to meet future demand.
"We believe this collaboration is a transformative step forward in our mission to commercialize sustainable, cost-effective spider silk. This rare opportunity is due, in large part, to the team we鈥檝e assembled, our commitment to excellence, and our progress in the field," said the Company鈥檚 COO, Jon Rice. "It provides us with strategic infrastructure and institutional support to grow our production footprint, while further reinforcing the stability and security of our operations through parallelized rearing and egg development systems."
Work under this agreement is anticipated to begin in August. This collaboration will serve as a foundational element of the Company鈥檚 expanding global spider silk manufacturing strategy, highlighting the growing confidence in the Company's pioneering biomaterials.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit .
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel .
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go聽to 听听
* For a description of our historical leadership in this technology, please follow this link
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
FAQ
What is the strategic partnership Kraig Biocraft (KBLB) announced in July 2025?
How will the new government collaboration affect KBLB's production capacity?
When will Kraig Biocraft's new government partnership begin operations?
What are the main benefits of KBLB's new production strategy?
How does this agreement impact Kraig Biocraft's manufacturing strategy?
